Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
The CVOT for retatrutide will be required before full FDA approval
These data show clearly that these new GLP-1 pharmaceutical class is actually a tailwind for our ResMed business, bringing more patients and more motivated patients into the healthcare system.
No oral options: Both compounds are subcutaneous only
Triplehormone-receptor agonist retatrutide for obesitya phase 2 trial
Not Grns clinical study
The cost of conducting the required pediatric studies is typically $30 million to $100 million a return-on-investment that makes pediatric exclusivity one of the clearest value-creation opportunities in pharmaceutical development
:max_bytes(150000):strip_icc()/VWH-MiraNorian-WeightLossDrugUpdate-4000x2700-c813fa5051604eec9c136047fb44d23a.png)
US$ 26.24
US$ 29.87
US$ 24.07
US$ 21.85
US$ 28.52
